Latest news with #ConestogaMicro-CapComposite
Yahoo
03-05-2025
- Business
- Yahoo
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare
Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical tensions, and an upcoming announcement on tariffs led to a sharp decline in equities by the end of the first quarter. Investors sought safety, driving U.S. Treasury yields down. The Conestoga Small Cap Composite returned -11.35% (net) in the first quarter compared to the Russell 2000 Growth Index's -11.12% return. The Conestoga SMid Cap Composite returned -5.73% compared to the Russell 2500 Growth Index's -10.80% return. The Conestoga Micro-Cap Composite returned -8.24% vs the Russell Microcap Growth Index's return of -17.75%. Finally, the Conestoga Mid Cap Composite returned 0.96% (net), compared to the Russell Midcap Growth Index's -7.12% return. Please check the top 5 holdings of the fund for a better understanding of their best picks for 2025. In its first-quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Repligen Corporation (NASDAQ:RGEN). Repligen Corporation (NASDAQ:RGEN) develops and distributes bioprocessing technologies and systems. The one-month return of Repligen Corporation (NASDAQ:RGEN) was 22.57%, and its shares lost 17.87% of their value over the last 52 weeks. On May 1, 2025, Repligen Corporation (NASDAQ:RGEN) stock closed at $137.20 per share with a market capitalization of $7.708 billion. Conestoga Capital Advisors stated the following regarding Repligen Corporation (NASDAQ:RGEN) in its Q1 2025 investor letter: "Repligen Corporation (NASDAQ:RGEN) is a provider of tools used by biotechnology companies. RGEN reported in-line Q4 2024 results and 2025 guidance. The stock rose on the earnings release but fell later in the quarter on rising uncertainty related to U.S. Federal Government spending on healthcare initiatives. Companies with exposure to the bio-processing industry remained under pressure during the first quarter of 2025. We maintain our high conviction in RGEN as we believe there are indications of improving fundamentals for the business." A technician in a lab inspecting an ELISA test kit for use in biopharmaceutical diagnostics. Repligen Corporation (NASDAQ:RGEN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held Repligen Corporation (NASDAQ:RGEN) at the end of the fourth quarter, compared to 34 in the third quarter. While we acknowledge the potential of Repligen Corporation (NASDAQ:RGEN) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Repligen Corporation (NASDAQ:RGEN) and shared the list of the best-performing stocks from the last 20 years, as listed by Jim Cramer. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
03-05-2025
- Business
- Yahoo
Is Verisk Analytics (VRSK) a Recession-Resistant Stock?
Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical tensions, and an upcoming announcement on tariffs led to a sharp decline in equities by the end of the first quarter. Investors sought safety, driving U.S. Treasury yields down. The Conestoga Small Cap Composite returned -11.35% (net) in the first quarter compared to the Russell 2000 Growth Index's -11.12% return. The Conestoga SMid Cap Composite returned -5.73% compared to the Russell 2500 Growth Index's -10.80% return. The Conestoga Micro-Cap Composite returned -8.24% vs the Russell Microcap Growth Index's return of -17.75%. Finally, the Conestoga Mid Cap Composite returned 0.96% (net), compared to the Russell Midcap Growth Index's -7.12% return. Please check the top 5 holdings of the fund for a better understanding of their best picks for 2025. In its first-quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Verisk Analytics, Inc. (NASDAQ:VRSK). Verisk Analytics, Inc. (NASDAQ:VRSK) offers data analytics solutions to the insurance markets. The one-month return of Verisk Analytics, Inc. (NASDAQ:VRSK) was 3.34%, and its shares gained 24.09% of their value over the last 52 weeks. On May 1, 2025, Verisk Analytics, Inc. (NASDAQ:VRSK) stock closed at $294.51 per share with a market capitalization of $41.215 billion. Conestoga Capital Advisors stated the following regarding Verisk Analytics, Inc. (NASDAQ:VRSK) in its Q1 2025 investor letter: "Verisk Analytics, Inc.'s (NASDAQ:VRSK) 4Q results were generally in line with the market's expectations. The company's organic revenue growth was 8.6% and adjusted EBITDA increased 9.8%. The resiliency of its business model is evidenced by its 2025 guidance. The company expects organic revenue growth of 7%, and EBITDA margin expansion of 70 basis points. Similar to ROL and WCN, VRSK's, recession-resistant sustainable growth and strong free cash flow business model is attractive to investors during highly uncertain market periods." An engineer using the latest predictive analytics software to formulate solutions. Verisk Analytics, Inc. (NASDAQ:VRSK) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held Verisk Analytics, Inc. (NASDAQ:VRSK) at the end of the fourth quarter which was 42 in the previous quarter. In the fourth quarter, Verisk Analytics, Inc. (NASDAQ:VRSK) generated $736 million in revenues, representing an increase of 8.6% from Q4 2023. While we acknowledge the potential of Verisk Analytics, Inc. (NASDAQ:VRSK) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Verisk Analytics, Inc. (NASDAQ:VRSK) and shared TimesSquare Capital Management U.S. Focus Growth Strategy's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
03-05-2025
- Business
- Yahoo
Should You Hold Bio-Techne Corp. (TECH) For the Long Term?
Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical tensions, and an upcoming announcement on tariffs led to a sharp decline in equities by the end of the first quarter. Investors sought safety, driving U.S. Treasury yields down. The Conestoga Small Cap Composite returned -11.35% (net) in the first quarter compared to the Russell 2000 Growth Index's -11.12% return. The Conestoga SMid Cap Composite returned -5.73% compared to the Russell 2500 Growth Index's -10.80% return. The Conestoga Micro-Cap Composite returned -8.24% vs the Russell Microcap Growth Index's return of -17.75%. Finally, the Conestoga Mid Cap Composite returned 0.96% (net), compared to the Russell Midcap Growth Index's -7.12% return. Please check the top 5 holdings of the fund for a better understanding of their best picks for 2025. In its first-quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $7.846 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -9.53%, and its shares lost 34.35% of their value over the last 52 weeks. On May 1, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $49.63 per share. Conestoga Capital Advisors stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2025 investor letter: "Bio-Techne Corporation (NASDAQ:TECH) makes and distributes biological research supplies used by researchers around the globe. The company reported a strong quarter, with 9% organic revenue growth and a recovery in large pharmaceutical customer orders. That said, shares came under pressure due to increased uncertainty around the U.S. regulatory and funding environment. We believe the noise around the funding environment is a near-term headwind but the long-term demand for new drug development will remain robust." A biopharmaceutical researcher proficiently using laboratory instruments. Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the fourth quarter compared to 25 in the third quarter. In the second quarter of fiscal 2025, the company generated $297 million in revenues, up 9% year-over-year on both reported and organic basis. While we acknowledge the potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Bio-Techne Corporation (NASDAQ:TECH) and shared Aristotle Atlantic Large Cap Growth Strategy's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
30-04-2025
- Business
- Yahoo
Do You Believe in the Growth Prospects of Transcat (TRNS)?
Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical tensions, and an upcoming announcement on tariffs led to a sharp decline in equities by the end of the first quarter. Investors sought safety, driving U.S. Treasury yields down. The Conestoga Small Cap Composite returned -11.35% (net) in the first quarter compared to the Russell 2000 Growth Index's -11.12% return. The Conestoga SMid Cap Composite returned -5.73% compared to the Russell 2500 Growth Index's -10.80% return. The Conestoga Micro-Cap Composite returned -8.24% vs the Russell Microcap Growth Index's return of -17.75%. Finally, the Conestoga Mid Cap Composite returned 0.96% (net), compared to the Russell Midcap Growth Index's -7.12% return. Please check the top 5 holdings of the fund for a better understanding of their best picks for 2025. In its first-quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Transcat, Inc. (NASDAQ:TRNS). Transcat, Inc. (NASDAQ:TRNS) offers calibration and laboratory instrument services. The one-month return of Transcat, Inc. (NASDAQ:TRNS) was 6.71%, and its shares lost 25.19% of their value over the last 52 weeks. On April 29, 2025, Transcat, Inc. (NASDAQ:TRNS) stock closed at $80.42 per share with a market capitalization of $748.668 million. Conestoga Capital Advisors stated the following regarding Transcat, Inc. (NASDAQ:TRNS) in its Q1 2025 investor letter: "Transcat, Inc. (NASDAQ:TRNS) engages in the provision of calibration and laboratory instrument services. TRNS reported weaker than expected operating results for Q3 Fiscal 2025. Softer revenue was in part driven by holiday timing as Christmas closures decreased quarter-end activity. In addition, Transcat Solutions, formally Nexa, was materially slower than year ago levels. Despite the near-term headwinds, management sees a path to return organic revenue growth to historic levels, potentially as early as the first half of fiscal 2026, which begins in April 2025." A technician inspecting a complex instrument, relics of advanced technology in the backdrop. Transcat, Inc. (NASDAQ:TRNS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 11 hedge fund portfolios held Transcat, Inc. (NASDAQ:TRNS) at the end of the fourth quarter which was 10 in the previous quarter. In the fiscal third quarter of 2025, Transcat, Inc.'s (NASDAQ:TRNS) consolidated revenue was up 2% to $66.8 million however, organic revenue fell 4% from prior year quarter. While we acknowledge the potential of Transcat, Inc. (NASDAQ:TRNS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Transcat, Inc. (NASDAQ:TRNS) and shared Headwaters Capital Management's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
